tipifarnib has been researched along with abt-737 in 1 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (abt-737) | Trials (abt-737) | Recent Studies (post-2010) (abt-737) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 632 | 0 | 484 |
| Protein | Taxonomy | tipifarnib (IC50) | abt-737 (IC50) |
|---|---|---|---|
| Bcl-2-like protein 11 | Homo sapiens (human) | 0.002 | |
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | 0.0206 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0003 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0003 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0003 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0003 | |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | 0.02 | |
| BH3-interacting domain death agonist | Homo sapiens (human) | 0.0485 | |
| Apoptosis regulator BAX | Homo sapiens (human) | 0.023 | |
| Bcl-2-like protein 1 | Homo sapiens (human) | 0.0207 | |
| Induced myeloid leukemia cell differentiation protein Mcl-1 | Homo sapiens (human) | 0.0248 | |
| Aspartyl/asparaginyl beta-hydroxylase | Homo sapiens (human) | 3.44 | |
| Bcl-2 homologous antagonist/killer | Homo sapiens (human) | 0.0335 | |
| Bcl-2-like protein 2 | Homo sapiens (human) | 0.0335 | |
| Bcl-2-binding component 3, isoforms 1/2 | Homo sapiens (human) | 0.0003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonovolias, ID; Chatzopoulou, M; Demopoulos, VJ; Nicolaou, I; Tsiftsoglou, AS; Vizirianakis, IS | 1 |
1 review(s) available for tipifarnib and abt-737
| Article | Year |
|---|---|
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multipotent Stem Cells; Neoplastic Stem Cells; Pharmacogenetics | 2010 |